What GHK-Cu actually is
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), a sequence that occurs naturally in human plasma and declines with age. Bound to copper, it is known as copper tripeptide-1 in cosmetic ingredient naming. It is one of the most-studied 'copper peptides' and appears in both the skincare literature and broader tissue-repair research.
Why copper peptides are studied in skin research
The research interest centers on skin remodeling and wound healing: GHK and GHK-Cu are studied for effects on extracellular matrix proteins (such as collagen), antioxidant signaling, and gene expression related to repair. The copper ion itself is a cofactor for enzymes involved in connective-tissue formation, which is part of why the copper complex—rather than the bare peptide—is the form usually discussed.
Cosmetic (topical) vs research (injectable) framing
This is the crucial distinction for readers. GHK-Cu appears widely in topical cosmetic products, where it is used as a skincare ingredient under cosmetic regulations. That is a very different context from injectable 'research peptide' use. Topical cosmetic use and systemic injectable use are not the same regulatory or evidence category, and conflating them is a common error—see our cosmetic vs research peptides guide.
GHK-Cu vs synthetic cosmetic peptides
GHK-Cu is often compared with synthetic cosmetic peptides such as Matrixyl (palmitoyl pentapeptides) and SNAP-8 (a botulinum-inspired peptide studied for expression-line appearance). These act through different proposed mechanisms—matrix stimulation versus neuromuscular-signal modulation—so they are studied for different cosmetic endpoints rather than being direct substitutes. Formulation, concentration, and delivery matter as much as the peptide identity.
What the evidence supports
There is a genuine body of laboratory and some clinical cosmetic research on GHK-Cu for skin appearance and wound-healing signaling, which is stronger than for many trend peptides. Even so, marketing claims frequently outrun the data, especially bold anti-aging or systemic 'regeneration' claims. Evidence for topical cosmetic effects should not be read as proof of injectable systemic benefit.
Regulatory and safety framing
Topical cosmetic GHK-Cu is regulated as a cosmetic ingredient; injectable use of GHK-Cu as a research peptide is a different matter and is not authorized by Health Canada for general human use. This guide is educational and does not provide dosing, formulation, or injection instructions.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Maquart et al. (1988) — GHK-Cu and collagen synthesis in fibroblast cultures
Cell-culture collagen endpoint, not a human injectable skin or hair trial.
Relevant sections: Why copper peptides are studied in skin research · What the evidence supports
- Maquart et al. (1993) — GHK-Cu in experimental wound models
Animal wound model; cosmetic formulation and human systemic exposure require separate evidence.
Relevant sections: Why copper peptides are studied in skin research · Cosmetic (topical) vs research (injectable) framing · What the evidence supports
- Health Canada (2026) — unauthorized injectable peptides bought online
Canadian safety and authorization notice for the products described. It does not establish approval status in every country.
Relevant sections: Regulatory and safety framing
FAQ
What is GHK-Cu?+
It is a copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK), known in cosmetics as copper tripeptide-1. It is one of the most-studied copper peptides in skin and tissue-repair research.
Is GHK-Cu the same as using it topically in skincare?+
No—context matters. Topical cosmetic GHK-Cu is regulated as a skincare ingredient, which is a different regulatory and evidence category from injectable 'research peptide' use. The two should not be conflated.
How does GHK-Cu compare to Matrixyl or SNAP-8?+
They act through different proposed mechanisms—GHK-Cu on matrix and repair signaling, Matrixyl on collagen-related stimulation, and SNAP-8 on neuromuscular signaling for expression lines—so they are studied for different cosmetic endpoints rather than being direct swaps.
Does GHK-Cu have real evidence behind it?+
It has a more substantial laboratory and cosmetic-research base than many trend peptides, particularly for topical skin appearance and wound-healing signaling. But bold anti-aging or systemic claims often exceed the data, and topical evidence does not prove injectable systemic benefit.